Antisense modulation of TGF-beta 2 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsBrett P. Monia, Susan M. Freier, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of TGF-beta 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TGF-beta 2. Methods of using these compounds for modulation of TGF-beta 2 expression and for treatment of diseases associated with expression of TGF-beta 2 are provided.
Claims20
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding TGF-beta 2, wherein said compound specifically hybridizes with said nucleic acid molecule encoding TGF-beta 2 and inhibits the expression of TGF-beta 2.
A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding TGF-beta 2.
A method of screening for an antisense compound, the method comprising the steps of:
- a. contacting a preferred target region of a nucleic acid molecule encoding TGF-beta 2 with one or more candidate antisense compounds, said candidate antisense compounds comprising at least an 8-nucleobase portion which is complementary to said preferred target region, and
- b. selecting for one or more candidate antisense compounds which inhibit the expression of a nucleic acid molecule encoding TGF-beta 2.
Dependencies are inferred from the claim text.